"The primary efficacy endpoint will be trajectory of PaO2/FiO2 ratio (a measure of hypoxemia, a low level of oxygen in the blood caused by compromised lung function) by Day 7. Safety and tolerability up to Day 28 will also be a primary endpoint."
Fast readout here.
and data for CRS/ Sepsis too and implications for IPF undergoing Potency tests currently at Monash.
Ann: First Patient Enrolled in Cynata MEND Clinical Trial, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
-0.010(5.41%) |
Mkt cap ! $39.54M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 18.5¢ | 17.5¢ | $3.782K | 21.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 7383 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 151530 | 4 |
View Market Depth
| Last trade - 13.48pm 22/07/2025 (20 minute delay) ? |
| CYP (ASX) Chart |